NeurAxis Expands Access to Percutaneous Electrical Nerve Field Stimulation with New Coverage Agreements in Pennsylvania and North Dakota
CARMEL, Ind. — NeurAxis, Inc. (NYSE American: NRXS), a pioneering medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, has made significant strides in expanding access to its innovative treatment, Percutaneous Electrical Nerve Field Stimulation (PENFS). Effective October 1, 2024, Capital Blue Cross will provide medical policy coverage for PENFS to its members in a 21-county region across Central Pennsylvania and the Lehigh Valley. This addition marks a crucial milestone for NeurAxis, as it broadens the availability of this treatment option and underscores the company’s commitment to improving patient outcomes.
Earlier this year, on April 23, 2024, NeurAxis celebrated another key achievement with the announcement of medical policy coverage for PENFS in North Dakota. The coverage is facilitated through a partnership with a Blue Cross Blue Shield licensee, which represents the largest health care provider in the state, insuring over 310,000 individuals. This policy is set to take effect on May 6, 2024, further enhancing the reach of NeurAxis’s novel therapeutic interventions.
The impact of these policy advancements cannot be understated. Chronic pain and related conditions often place tremendous physical and emotional burdens on patients, significantly impairing their quality of life. NeurAxis’s focus on delivering effective neuromodulation therapies addresses the urgent need for alternative treatment modalities. By obtaining coverage agreements with major health insurers like Capital Blue Cross and BCBS of North Dakota, NeurAxis not only validates the efficacy and necessity of PENFS but also ensures that more individuals have access to this valuable therapy.
NeurAxis’s trajectory within the medical technology sphere highlights the importance of fluid partnerships between innovative companies and health plans. The strategic alignment opens doors for improved patient access, thereby enhancing treatment options for those suffering from chronic ailments. Investors also appear optimistic, as evidenced by the 1.2% rise in NeurAxis’s share price above its 52-week average on the NYSE American, reflecting increased confidence in the company’s prospects and the ongoing demand for effective chronic pain management solutions.
In conclusion, NeurAxis’s recent developments in medical policy coverage for PENFS represent a noteworthy achievement, reinforcing the company’s standing as a leader in the neuromodulation field. As healthcare providers and insurers recognize the value of innovative therapies, the potential for improved outcomes for patients grappling with chronic and debilitating conditions becomes increasingly attainable. The path forward looks promising for NeurAxis, paving the way for substantial advancements in patient care and quality of life for years to come.
Comments